{"id":"NCT01590771","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Sulfonylurea With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-253)","officialTitle":"A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial in China to Study the Safety and Efficacy of the Addition of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sulfonylurea Therapy, Alone or in Combination With Metformin","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-07-09","primaryCompletion":"2014-06-10","completion":"2014-06-24","firstPosted":"2012-05-03","resultsPosted":"2015-05-04","lastUpdate":"2018-08-17"},"enrollment":498,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Sitagliptin","otherNames":["JanuviaÂ®","MK-0431"]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Gliclazide","otherNames":[]},{"type":"DRUG","name":"Glimepiride","otherNames":[]},{"type":"DRUG","name":"Metformin","otherNames":[]}],"arms":[{"label":"Sitagliptin","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"A study to compare safety and efficacy of sitagliptin and placebo therapy when added to stable sulfonylurea alone or in combination with metformin in participants with type 2 diabetes mellitus (T2DM). The primary hypothesis of this study is that after 24 weeks, the addition of sitagliptin compared with placebo provides greater reduction in hemoglobin A1C (HbA1C) in T2DM participants on sulfonylurea alone or in combination with metformin.","primaryOutcome":{"measure":"Change From Baseline in A1C Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea Alone or in Combination With Metformin","timeFrame":"Baseline and Week 24","effectByArm":[{"arm":"Sitagliptin","deltaMin":-0.88,"sd":null},{"arm":"Placebo","deltaMin":-0.27,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":16},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["27502307"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":248},"commonTop":["Hypoglycaemia","Urinary tract infection","Hyperlipidaemia"]}}